What is Diabeloop?
Founded in 2015 by Dr. Guillaume Charpentier and Erik Huneker, Diabeloop operates at the intersection of medical research and digital health. The company specializes in developing automated insulin delivery systems that integrate with continuous glucose monitors to provide real-time, personalized therapeutic adjustments. By reducing the need for manual intervention, Diabeloop addresses a critical gap in chronic disease management, positioning itself as a leader in the digital health ecosystem. The company maintains a strong collaborative framework with research institutions like CEA-Leti, ensuring its technological advancements remain grounded in rigorous clinical validation.
How much funding has Diabeloop raised?
Diabeloop has raised a total of $141.1M across 4 funding rounds:
Series A
$15.8M
Unspecified
$16.3M
Series B
$34M
Series C
$75M
Series A (2017): $15.8M with participation from Sofimac Investment Managers, Kreaxi, and Crédit Agricole CIB
Unspecified (2017): $16.3M, investors not publicly disclosed
Series B (2019): $34M supported by Odyssée Venture, AGIR à dom, CEMAG, and ADAG
Series C (2022): $75M featuring Innovacom, LBO France, and Terumo Corporation
Key Investors in Diabeloop
Innovacom
A seasoned venture capital firm with over three decades of experience, Innovacom focuses on supporting high-potential digital startups and industrial innovation across diverse sectors including medical imaging and digital health.
LBO France
A prominent private equity firm with a strong commitment to ESG principles, LBO France specializes in transforming mid-cap companies and investing in innovative sectors such as digital health to create sustainable value.
Kreaxi
An investment management firm specializing in equity financing for innovative tech startups, Kreaxi provides both capital and strategic guidance to companies during their acceleration and development phases.
What's next for Diabeloop?
With the recent influx of capital, Diabeloop is poised to scale its commercial operations and deepen its market penetration across Europe and beyond. The strategic focus will likely center on expanding the clinical application of its automated systems and enhancing its software-as-a-medical-device (SaMD) portfolio. As the company transitions into a more mature enterprise phase, it will continue to leverage its partnerships with global medical technology leaders to integrate its solutions into broader healthcare infrastructures, ultimately aiming to set a new standard for patient-centric diabetes care.
See full Diabeloop company page
